Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alar Pharmaceuticals Buyback Yield % Related Terms
Alar Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6785 vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals (ROCO:6785) has a Buyback Yield % of 0.00 as of Jul. 24, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Alar Pharmaceuticals and its competitors. According to the industry distribution chart, Alar Pharmaceuticals ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Alar Pharmaceuticals' Buyback Yield % too high?
Alar Pharmaceuticals' current Buyback Yield % is 0.00. Based on the distribution chart, Alar Pharmaceuticals ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #999999 out of 290 companies for Buyback Yield %. This places Alar Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Alar Pharmaceuticals and its competitors. Alar Pharmaceuticals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$96.24, compared to a current price of NT$108.50 — trading 12.7% above its estimated fair value. The current Buyback Yield % is 0.00. Alar Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Buyback Yield % is 0.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$108.50 is trading 12.7% above its estimated GF Value™ of NT$96.24.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
Buyback Yield %: 0.00
GF Value™: NT$96.24 vs. price of NT$108.50 (12.7% above fair value)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
53GF Score
Get the complete analysis for ROCO:6785
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
